Tuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor Activity. - Wikidata - awgldk - TriplyDB

Tuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor Activity.

Tuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor Activity.

http://www.wikidata.org/entity/Q36218880

about

CAR models: next-generation CAR modifications for enhanced T-cell function New Strategies for the Treatment of Solid Tumors with CAR-T Cells Chimeric Antigen Receptor-Modified T Cells for Solid Tumors: Challenges and Prospects Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy Immune Responses to Epidermal Growth Factor Receptor (EGFR) and Their Application for Cancer Treatment Immunotherapy of Malignant Tumors in the Brain: How Different from Other Sites?Recent advances in T-cell engineering for use in immunotherapy Structural basis for cancer immunotherapy by the first-in-class checkpoint inhibitor ipilimumab An oxygen sensitive self-decision making engineered CAR T-cell.Masked Chimeric Antigen Receptor for Tumor-Specific Activation.Bispecific antibodies and CARs: generalized immunotherapeutics harnessing T cell redirection.Smart CARS: optimized development of a chimeric antigen receptor (CAR) T cell targeting epidermal growth factor receptor variant III (EGFRvIII) for glioblastoma Immunotherapy in glioblastoma: emerging options in precision medicine Prioritization schema for immunotherapy clinical trials in glioblastoma.Architecture of a minimal signaling pathway explains the T-cell response to a 1 million-fold variation in antigen affinity and dose.CAR-T cell therapy in gastrointestinal tumors and hepatic carcinoma: From bench to bedside.Cocktail treatment with EGFR-specific and CD133-specific chimeric antigen receptor-modified T cells in a patient with advanced cholangiocarcinoma.Chimaeric antigen receptor T-cell therapy for tumour immunotherapy.New development in CAR-T cell therapy.Adoptive T Cell Therapies: A Comparison of T Cell Receptors and Chimeric Antigen Receptors Bioengineering solutions for manufacturing challenges in CAR T cells.Tumor Antigen and Receptor Densities Regulate Efficacy of a Chimeric Antigen Receptor Targeting Anaplastic Lymphoma Kinase.Treatment of solid tumors with chimeric antigen receptor-engineered T cells: current status and future prospects.Driving gene-engineered T cell immunotherapy of cancer.Spotlight on chimeric antigen receptor engineered T cell research and clinical trials in China.Synthetic biology approaches in cancer immunotherapy, genetic network engineering, and genome editing.SHP-1: the next checkpoint target for cancer immunotherapy?How Chimeric Antigen Receptor Design Affects Adoptive T Cell Therapy.T-lymphocyte homing: an underappreciated yet critical hurdle for successful cancer immunotherapy.Shared target antigens on cancer cells and tissue stem cells: go or no-go for CAR T cells?Tumor-targeting domains for chimeric antigen receptor T cells.The Principles of Engineering Immune Cells to Treat Cancer.Targeting Ewing sarcoma with activated and GD2-specific chimeric antigen receptor-engineered human NK cells induces upregulation of immune-inhibitory HLA-G.CARs: Synthetic Immunoreceptors for Cancer Therapy and Beyond.Engineering Chimeric Antigen Receptor T-Cells for Racing in Solid Tumors: Don't Forget the Fuel Increasing the safety and efficacy of chimeric antigen receptor T cell therapy.Current status and perspectives of chimeric antigen receptor modified T cells for cancer treatment.The Multi-Purpose Tool of Tumor Immunotherapy: Gene-Engineered T Cells.Therapeutic T cell engineering.Turn to TCRs when CARs fail.

P2860

Q26745600-8A402895-A3DA-4495-BC5F-015D8B03190C Q26748500-EC6BA88E-5510-44C0-8A4B-E8BAA8DD0E0A Q26753082-AD696D17-6855-4305-A1E7-97B688BFBFCE Q26773309-324A03DB-176A-4A41-85DE-30FFC42B9078 Q28069424-EA98B280-5DF1-4693-8475-D59F624CB46E Q28078539-BC2BCC82-72D3-43F2-A14E-B4174FA02D66 Q28080312-DE783A9C-9633-4AD3-B830-477F54CBBC6C Q30274619-C8B7419E-D789-48A2-B4FF-C246C2605DB6 Q34047851-E1348442-1D71-42D7-82E5-1E17D6FA7DAA Q34047878-1AF0FA21-D37C-4322-A59F-EFAEF00E6FCF Q34517676-AC46C07C-4839-4654-A986-DC288762F991 Q36474226-3F9B9E1F-9FF9-4881-904E-5F33A729F07C Q37050960-F0D74B06-1A5A-42AC-99BE-24CBE620B9E8 Q37078999-4E9C3E8F-1157-4332-B1DF-7126F34649F6 Q37379865-EF42C630-0590-4969-BB08-BEF3DEE8C5D4 Q37559401-840F6D18-EA98-4D50-AF27-293A2E553B92 Q37566921-B74C12DD-8C10-4B6A-A22F-89EE8DB49C59 Q37609801-7D09FFE4-24DA-4108-8F6C-C7EF32C9C5B6 Q37658246-520BFA9E-3079-4876-B4A9-21D941A0D599 Q38603686-0B449A24-179C-4283-A250-D320161AE2EB Q38637370-7A2C5212-AD38-461D-BF03-AC8FE045B309 Q38694036-7856B243-7EB4-48C3-AC57-3458DC0AB104 Q38770555-238ED8DF-230F-4474-9258-B0148DEB9DA6 Q38777742-89E0DC82-FC56-4F0C-AEE1-24AFAF3B1383 Q38786626-73545521-CB6C-4F2A-B831-497FD317C0AD Q38805497-CDDF2A57-85A5-4A94-8177-5A07AD626D61 Q38805738-9272869D-3A00-44D8-AAE2-175890FC21FF Q38830813-B332CC50-4FF3-4718-B5AF-E4A0C0B88CA2 Q38873974-B85C4092-2E40-4A16-AF41-408C85D417CA Q38933510-D35931A8-DC1C-4B0D-A0C3-EFE7467D5CD2 Q39045535-7806E6EF-2164-4A5E-BCB7-2456457969C0 Q39130457-3480CD88-CDC2-4AEB-A596-C3188ED0A994 Q39135703-D85D1BBB-4D66-4348-8D9D-CBD45CF49B6A Q39246685-74199AE2-36BF-4C24-B422-B25E5EF58B71 Q39249589-383E303D-83C8-4F36-8646-1D0429857CE1 Q39256918-B582B7F3-EF81-4A52-B7DB-3C4072A824FA Q39280002-1693ACC6-0E47-4290-B49C-F5D308B82E75 Q40095245-B4F088D9-B8D0-4422-8C3E-81A5CC3081BA Q40199809-98F4E5B6-5313-4541-8555-6CC310473B14 Q42315772-DA261488-8508-4D10-99CA-C34CCD547BE0

P2860

Tuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor Activity.

http://www.wikidata.org/entity/Q36218880

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Tuning Sensitivity of CAR to E ...... ing Potent Antitumor Activity.

@ast

Tuning Sensitivity of CAR to E ...... ing Potent Antitumor Activity.

@en

type

label

Tuning Sensitivity of CAR to E ...... ing Potent Antitumor Activity.

@ast

Tuning Sensitivity of CAR to E ...... ing Potent Antitumor Activity.

@en

prefLabel

Tuning Sensitivity of CAR to E ...... ing Potent Antitumor Activity.

@ast

Tuning Sensitivity of CAR to E ...... ing Potent Antitumor Activity.

@en

P1433

Q36218880-0B5F99E8-370B-48EE-8CD5-06A503596B68

P1476

Q36218880-7B65F474-2B67-4F80-8085-2ABCD4C585ED

P2093

Q36218880-11CFDA6E-3CE2-4F19-B40F-CEFD9E27F5AE

Q36218880-1F750111-31B8-477C-A1A0-667EE3D045C7

Q36218880-348721C9-96D4-4577-B87E-60FC89A3E7D7

Q36218880-3BD14B14-BF0C-451D-A15C-45C95F80FE3E

Q36218880-49634F55-D8DE-407E-83F5-183A73F7DF47

Q36218880-4C206386-BEB9-45E2-A166-EA1D08BC888E

Q36218880-8BC37A88-4E74-4B5E-8526-383FA6C6D126

Q36218880-984E5F01-7C4A-44CF-A93F-9EE860F836BF

Q36218880-A85F8F2A-18E3-44B3-9EEA-2648A56189D0

Q36218880-A923DEC6-48BD-4974-AD30-A4B178814EDE

P2860

Q36218880-00BB18BA-84D7-4EA4-8EA8-2520840092F3

Q36218880-0416EAEF-9550-45CA-9165-79BE5795088E

Q36218880-0D93D836-2CA4-476A-BC31-8280B3846315

Q36218880-119D0EAF-EAFF-414C-86B8-A63F5BFBE90F

Q36218880-13503738-B70D-48F4-A742-D283A84E720B

Q36218880-17AFBD09-ABA3-4EE2-B910-B1FE370C382C

Q36218880-17B9467B-45EF-4064-BE6D-EB37872AEB83

Q36218880-1C1A02D6-D2CD-44B8-B839-DFB9A6179F70

Q36218880-234C760A-D005-4807-81A9-63591822168B

Q36218880-2378F4A9-D795-4DA4-B093-5CD0144BB610

P304

Q36218880-54209CD3-F979-4210-8467-AE979A3F0BF4

P31

Q36218880-7D40A3DA-BDE9-4AF3-9BBC-F430D55636C9

P356

Q36218880-F623D444-1A63-4323-8923-AE8A81DCF8B7

P407

Q36218880-276FB7AE-ED1E-45B7-8FB6-630F6DC1F652

P433

Q36218880-3525CA72-03B3-46BD-8638-8B83F0A4D46D

P478

Q36218880-00AEF453-9D03-4381-872F-BF9500A031C8

P50

Q36218880-DA161CE1-04ED-4DA0-B75E-90F0EBB1492C

P577

Q36218880-0A9BA154-7FC6-4E6F-98B5-C15E92C398D7

P5875

Q36218880-E42A97D9-E637-4D12-BDBC-88C34DBD62D6

P698

Q36218880-E0475BF8-8DCB-4302-880E-3D394EE9CE7F

P932

Q36218880-F02E5FCE-9667-4A48-B940-84AE3E89B810

P356

0008-5472.CAN-15-0139

P1433

Cancer Research

P1476

Tuning Sensitivity of CAR to E ...... ing Potent Antitumor Activity.

@en

P2093

Amer Najjar

http://www.w3.org/2001/XMLSchema#string

Amy B Heimberger

http://www.w3.org/2001/XMLSchema#string

David Rushworth

http://www.w3.org/2001/XMLSchema#string

Harjeet Singh

http://www.w3.org/2001/XMLSchema#string

Helen Huls

http://www.w3.org/2001/XMLSchema#string

Hillary G Caruso

http://www.w3.org/2001/XMLSchema#string

Kirsten Switzer

http://www.w3.org/2001/XMLSchema#string

Laurence J N Cooper

http://www.w3.org/2001/XMLSchema#string

Lenka V Hurton

http://www.w3.org/2001/XMLSchema#string

Richard E Champlin

http://www.w3.org/2001/XMLSchema#string

P2860

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

Nimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks ligand binding while permitting the active receptor conformation

Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies

Chimeric antigen receptor T cells for sustained remissions in leukemia

Inducible apoptosis as a safety switch for adoptive cell therapy

Chimeric antigen receptor-modified T cells for acute lymphoid leukemia

CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011.

EGFR-targeted therapy in malignant glioma: novel aspects and mechanisms of drug resistance.

Distinct influences of peptide-MHC quality and quantity on in vivo T-cell responses.

PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses

P304

3505-3518

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/0008-5472.CAN-15-0139

http://www.w3.org/2001/XMLSchema#string

P407

P433

17

http://www.w3.org/2001/XMLSchema#string

P478

75

http://www.w3.org/2001/XMLSchema#string

P50

P577

2015-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

281517856

http://www.w3.org/2001/XMLSchema#string

P698

26330164

http://www.w3.org/2001/XMLSchema#string

P932

4624228

http://www.w3.org/2001/XMLSchema#string